Michael D Chan
Overview
Explore the profile of Michael D Chan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
170
Citations
3026
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Smith M, Wang Y, Dixon C, DAgostino R, Liu Y, Ruiz J, et al.
Clin Lung Cancer
. 2024 Aug;
25(8):e379-e388.
PMID: 39095235
Objectives: Compared to low-grade irAEs, high-grade irAEs are more often dose-limiting and can alter the long-term treatment options for a patient. Predicting the incidence of high-grade irAEs would help with...
12.
Qian X, Tan H, Liu X, Zhao W, Chan M, Kim P, et al.
Genes (Basel)
. 2024 Jun;
15(6).
PMID: 38927654
Glioblastoma multiforme (GBM)is the most common and aggressive primary brain tumor. Although temozolomide (TMZ)-based radiochemotherapy improves overall GBM patients' survival, it also increases the frequency of false positive post-treatment magnetic...
13.
Wang D, Geng H, Gondi V, Lee N, Tsien C, Xia P, et al.
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893130
The quality of radiation therapy (RT) treatment plans directly affects the outcomes of clinical trials. KBP solutions have been utilized in RT plan quality assurance (QA). In this study, we...
14.
Gallitto M, Sedor G, Lee A, Pasetsky J, Kinslow C, De Los Santos G, et al.
Int J Radiat Oncol Biol Phys
. 2024 Apr;
120(3):730-737.
PMID: 38641234
Purpose: The role of stereotactic radiosurgery (SRS) in the management of grade 2 and 3 meningiomas is not well elucidated. Unfortunately, local recurrence rates are high, and guidelines for management...
15.
Gallitto M, Pan P, Chan M, Milano M, Wang T
Neuro Oncol
. 2024 Mar;
26(12 Suppl 2):S66-S75.
PMID: 38437664
The clinical efficacy and relative tolerability of adverse effects of immune checkpoint immunotherapy have led to its increasingly routine use in the management of multiple advanced solid malignancies. Radiation therapy...
16.
Ressler H, Cramer C, Isom S, McCormack M, Ruiz J, Xing F, et al.
Clin Neurol Neurosurg
. 2024 Feb;
238:108191.
PMID: 38422744
Objective: The objective of this study was to examine survival outcomes in 136 patients with renal cell carcinoma with metastases to the brain who were treated with radiation combined with...
17.
Abdulhaleem M, Hunting J, Wang Y, Smith M, Agostino R, Lycan T, et al.
Front Oncol
. 2023 Nov;
13:1214126.
PMID: 38023147
Background: Clinical biomarkers for brain metastases remain elusive. Increased availability of genomic profiling has brought discovery of these biomarkers to the forefront of research interests. Method: In this single institution...
18.
Williams M, Sohrabi A, Kittel C, White J, Cramer C, Lanier C, et al.
World Neurosurg
. 2023 Oct;
181:e453-e458.
PMID: 37865197
Objective: Imaging changes after stereotactic radiosurgery (SRS) can occur for years after treatment, although the available data on the incidence of tumor progression and adverse radiation effects (ARE) are generally...
19.
Song Q, Ruiz J, Xing F, Lo H, Craddock L, Pullikuth A, et al.
Commun Biol
. 2023 Jul;
6(1):760.
PMID: 37479733
Brain metastases is the most common intracranial tumor and account for approximately 20% of all systematic cancer cases. It is a leading cause of death in advanced-stage cancer, resulting in...
20.
Farris J, Hughes R, Razavian N, Pearce J, Snavely A, Chan M, et al.
Adv Radiat Oncol
. 2023 Jun;
8(3):101058.
PMID: 37273925
Purpose: Brain metastases (BMs) are a common source of morbidity and mortality. Guidelines do not advise brain surveillance for locally advanced non-small cell lung cancer (LA-NSCLC). We describe the incidence,...